Compare CPSS & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CPSS | PLX |
|---|---|---|
| Founded | 1991 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 191.4M | 204.9M |
| IPO Year | 1992 | 1998 |
| Metric | CPSS | PLX |
|---|---|---|
| Price | $9.38 | $1.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 23.1K | ★ 529.2K |
| Earning Date | 11-10-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.80 | 0.07 |
| Revenue | ★ $196,531,000.00 | $61,840,000.00 |
| Revenue This Year | $139.62 | $14.29 |
| Revenue Next Year | $10.58 | $16.65 |
| P/E Ratio | ★ $11.50 | $25.92 |
| Revenue Growth | 6.67 | ★ 35.41 |
| 52 Week Low | $6.67 | $1.32 |
| 52 Week High | $12.73 | $3.10 |
| Indicator | CPSS | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 66.09 | 44.81 |
| Support Level | $8.39 | $1.68 |
| Resistance Level | $8.74 | $1.78 |
| Average True Range (ATR) | 0.25 | 0.09 |
| MACD | 0.09 | 0.02 |
| Stochastic Oscillator | 80.69 | 78.57 |
Consumer Portfolio Services Inc is a U.S based company operating in the specialty finance sector. Its business is to purchase and service retail automobile contracts originated by franchised automobile dealers and, to a lesser extent by select independent dealers in the United States in the sale of new and used automobiles, light trucks, and passenger vans. Through its automobile contract purchases, the company provides indirect financing to the customers of dealers having limited credit histories, low incomes, or past credit problems, who it refers to as sub-prime customers. It serves as an alternative source of financing for dealers, facilitating sales to customers.
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.